Abstract
The toxicity of α-synuclein in the neuropathology of Parkinson’s disease which includes its hallmark aggregation has been studied scrupulously in the last decade. Although little is known regarding the normal functions of α-synuclein, its association with membrane phospholipids suggests its potential role in signaling pathways. Following extensive evidences for its nuclear localization, we and others recently demonstrated DNA binding activity of α-synuclein that modulates its conformation as well as aggregation properties. Furthermore, we also underscored the similarities among various amyloidogenic proteins involved in neurodegenerative diseases including amyloid beta peptides and tau. Our more recent studies show that α-synuclein is glycated and glycosylated both in vitro and in neurons, significantly affecting its folding, oligomeric, and DNA binding properties. Glycated α-synuclein causes increased genome damage both via its direct interaction with DNA and by increased generation of reactive oxygen species as glycation byproduct. In this review, we discuss the mechanisms of glycation and other posttranslational modifications of α-synuclein, including phosphorylation and nitration, and their role in neuronal death in Parkinson’s disease.
Similar content being viewed by others
References
Izumi Y, Kume T, Akaike A (2011) Regulation of dopaminergic neuronal death by endogenous dopamine and proteasome activity. Yakugaku Zasshi 131(1):21–27
Heisters D (2011) Parkinson’s: symptoms, treatments and research. Br J Nurs 20(9):548–554
Shulman JM, De Jager PL, Feany MB (2011) Parkinson’s disease: genetics and pathogenesis. Annu Rev Pathol 6:193–222. doi:10.1146/annurev-pathol-011110-130242
Hegde ML, Vasudevaraju P, Rao KJ (2010) DNA induced folding/fibrillation of alpha-synuclein: new insights in Parkinson’s disease. Front Biosci 15:418–436
Defebvre L (2010) Parkinson’s disease: role of genetic and environment factors. Involvement in everyday clinical practice. Rev Neurol (Paris) 166(10):764–769. doi:10.1016/j.neurol.2010.07.014
Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31(7):763–780. doi:10.1002/humu.21277
Martin I, Dawson VL, Dawson TM (2010) The impact of genetic research on our understanding of Parkinson’s disease. Prog Brain Res 183:21–41. doi:10.1016/S0079-6123(10)83002-X
Martin I, Dawson VL, Dawson TM (2011) Recent advances in the genetics of Parkinson’s disease. Annu Rev Genomics Hum Genet 12:301–325. doi:10.1146/annurev-genom-082410-101440
Pagon RA, Bird TD, Dolan CR et al (eds) (1993) GeneReviews™ [Internet]. University of Washington, Seattle, WA. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1116/
Hegde ML, Jagannatha Rao KS (2003) Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson’s disease. Arch Biochem Biophys 418(2):169–178
Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8(8):2804–2815
Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein. Cell 123(3):359–361. doi:10.1016/j.cell.2005.10.017
Chandra S, Gallardo G, Fernandez-Chacon R, Schluter OM, Sudhof TC (2005) Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123(3):383–396. doi:10.1016/j.cell.2005.09.028
Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22(20):8797–8807
Lykkebo S, Jensen PH (2002) Alpha-synuclein and presynaptic function: implications for Parkinson’s disease. Neuromolecular Med 2(2):115–129. doi:10.1385/NMM:2:2:115
Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25(1):239–252
Lee FJ, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J 15(6):916–926
Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL (2002) Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein. J Biol Chem 277(8):6344–6352. doi:10.1074/jbc.M108414200
Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M (1998) Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J Biol Chem 273(41):26292–26294
Bodner RA, Housman DE, Kazantsev AG (2006) New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle 5(14):1477–1480
Kazantsev AG, Kolchinsky AM (2008) Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease. Arch Neurol 65(12):1577–1581. doi:10.1001/archneur.65.12.1577
Yamin G, Uversky VN, Fink AL (2003) Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett 542(1–3):147–152
Auluck PK, Caraveo G, Lindquist S (2010) Alpha-synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol 26:211–233. doi:10.1146/annurev.cellbio.042308.113313
Uversky VN, Li J, Souillac P, Millett IS, Doniach S, Jakes R, Goedert M, Fink AL (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J Biol Chem 277(14):11970–11978. doi:10.1074/jbc.M109541200
Gadad BS, Britton GB, Rao KS (2011) Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. J Alzheimers Dis 24(Suppl 2):223–232. doi:10.3233/JAD-2011-110182
Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT Jr (1996) NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35(43):13709–13715. doi:10.1021/bi961799n
Uversky VN, Li J, Fink AL (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276(14):10737–10744. doi:10.1074/jbc.M010907200
Eliezer D, Kutluay E, Bussell R Jr, Browne G (2001) Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307(4):1061–1073. doi:10.1006/jmbi.2001.4538
Uversky VN (2003) A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn 21(2):211–234
Brown DR (2010) Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life 62(5):334–339. doi:10.1002/iub.316
Oueslati A, Fournier M, Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson’s disease pathogenesis and therapies. Prog Brain Res 183:115–145. doi:10.1016/S0079-6123(10)83007-9
Uversky VN (2007) Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 103(1):17–37. doi:10.1111/j.1471-4159.2007.04764.x
Stefani M (2010) Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. Febs J 277(22):4602–4613. doi:10.1111/j.1742-4658.2010.07889.x
van Rooijen BD, Claessens MM, Subramaniam V (2010) Membrane permeabilization by oligomeric alpha-synuclein: in search of the mechanism. PLoS One 5(12):e14292. doi:10.1371/journal.pone.0014292
Uversky VN, Li J, Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson’s disease and heavy metal exposure. J Biol Chem 276(47):44284–44296. doi:10.1074/jbc.M105343200
Santner A, Uversky VN (2010) Metalloproteomics and metal toxicology of alpha-synuclein. Metallomics 2(6):378–392. doi:10.1039/b926659c
Gupta VB, Hegde ML, Rao KS (2006) Role of protein conformational dynamics and DNA integrity in relevance to neuronal cell death in neurodegeneration. Curr Alzheimer Res 3(4):297–309
Hegde ML, Rao KS (2007) DNA induces folding in alpha-synuclein: understanding the mechanism using chaperone property of osmolytes. Arch Biochem Biophys 464(1):57–69. doi:10.1016/j.abb.2007.03.042
Bartels T, Choi JG, Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477(7362):107–110. doi:10.1038/nature10324
Polymeropoulos MH, Higgins JJ, Golbe LI, Johnson WG, Ide SE, Di Iorio G, Sanges G, Stenroos ES, Pho LT, Schaffer AA, Lazzarini AM, Nussbaum RL, Duvoisin RC (1996) Mapping of a gene for Parkinson’s disease to chromosome 4q21-q23. Science 274(5290):1197–1199
Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23(4):228–242. doi:10.1177/0891988710383572
Nuytemans K, Meeus B, Crosiers D, Brouwers N, Goossens D, Engelborghs S, Pals P, Pickut B, Van den Broeck M, Corsmit E, Cras P, De Deyn PP, Del-Favero J, Van Broeckhoven C, Theuns J (2009) Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population. Hum Mutat 30(7):1054–1061. doi:10.1002/humu.21007
Nishioka K, Ross OA, Ishii K, Kachergus JM, Ishiwata K, Kitagawa M, Kono S, Obi T, Mizoguchi K, Inoue Y, Imai H, Takanashi M, Mizuno Y, Farrer MJ, Hattori N (2009) Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 24(12):1811–1819. doi:10.1002/mds.22682
Biere AL, Wood SJ, Wypych J, Steavenson S, Jiang Y, Anafi D, Jacobsen FW, Jarosinski MA, Wu GM, Louis JC, Martin F, Narhi LO, Citron M (2000) Parkinson’s disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs. J Biol Chem 275(44):34574–34579. doi:10.1074/jbc.M005514200
Yonetani M, Nonaka T, Masuda M, Inukai Y, Oikawa T, Hisanaga S, Hasegawa M (2009) Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem 284(12):7940–7950. doi:10.1074/jbc.M807482200
Rospigliosi CC, McClendon S, Schmid AW, Ramlall TF, Barre P, Lashuel HA, Eliezer D (2009) E46K Parkinson’s-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J Mol Biol 388(5):1022–1032. doi:10.1016/j.jmb.2009.03.065
Puschmann A, Ross OA, Vilarino-Guell C, Lincoln SJ, Kachergus JM, Cobb SA, Lindquist SG, Nielsen JE, Wszolek ZK, Farrer M, Widner H, van Westen D, Hagerstrom D, Markopoulou K, Chase BA, Nilsson K, Reimer J, Nilsson C (2009) A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 15(9):627–632. doi:10.1016/j.parkreldis.2009.06.007
Michell AW, Barker RA, Raha SK, Raha-Chowdhury R (2005) A case of late onset sporadic Parkinson’s disease with an A53T mutation in alpha-synuclein. J Neurol Neurosurg Psychiatry 76(4):596–597. doi:10.1136/jnnp.2004.046425
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55(2):164–173. doi:10.1002/ana.10795
Grimm S, Hoehn A, Davies KJ, Grune T (2011) Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res 45(1):73–88. doi:10.3109/10715762.2010.512040
Wu KP, Kim S, Fela DA, Baum J (2008) Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. J Mol Biol 378(5):1104–1115. doi:10.1016/j.jmb.2008.03.017
Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281(40):29739–29752. doi:10.1074/jbc.M600933200
Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, Lamberto GR, Fernandez CO, Schmid A, Chegini F, Gai WP, Chiappe D, Moniatte M, Schneider BL, Aebischer P, Eliezer D, Zweckstetter M, Masliah E, Lashuel HA (2010) Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci 30(9):3184–3198. doi:10.1523/JNEUROSCI.5922-09.2010
Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285(4):2807–2822. doi:10.1074/jbc.M109.081950
Negro A, Brunati AM, Donella-Deana A, Massimino ML, Pinna LA (2002) Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. Faseb J 16(2):210–212. doi:10.1096/fj.01-0517fje
Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest 110(10):1429–1439. doi:10.1172/JCI15777
Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, Sage D, Abbas-Terki T, Iwatsubo T, Unser M, Aebischer P (2009) Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson’s disease. Hum Mol Genet 18(5):872–887. doi:10.1093/hmg/ddn417
Malkus KA, Tsika E, Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4:24. doi:10.1186/1750-1326-4-24
Ditaranto K, Tekirian TL, Yang AJ (2001) Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer’s disease. Neurobiol Dis 8(1):19–31. doi:10.1006/nbdi.2000.0364
Uversky VN, Yamin G, Souillac PO, Goers J, Glaser CB, Fink AL (2002) Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett 517(1–3):239–244
Yamin G, Glaser CB, Uversky VN, Fink AL (2003) Certain metals trigger fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem 278(30):27630–27635. doi:10.1074/jbc.M303302200
Uversky VN, Yamin G, Munishkina LA, Karymov MA, Millett IS, Doniach S, Lyubchenko YL, Fink AL (2005) Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res Mol Brain Res 134(1):84–102. doi:10.1016/j.molbrainres.2004.11.014
Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H (2000) Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275(24):18344–18349. doi:10.1074/jbc.M000206200
Hodara R, Norris EH, Giasson BI, Mishizen-Eberz AJ, Lynch DR, Lee VM, Ischiropoulos H (2004) Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J Biol Chem 279(46):47746–47753. doi:10.1074/jbc.M408906200
Uchida K, Sakai K, Itakura K, Osawa T, Toyokuni S (1997) Protein modification by lipid peroxidation products: formation of malondialdehyde-derived N(epsilon)-(2-propenol)lysine in proteins. Arch Biochem Biophys 346(1):45–52
Vicente Miranda H, Outeiro TF (2010) The sour side of neurodegenerative disorders: the effects of protein glycation. J Pathol 221(1):13–25. doi:10.1002/path.2682
Padmaraju V, Bhaskar JJ, Prasada Rao UJ, Salimath PV, Rao KS (2011) Role of advanced glycation on aggregation and DNA binding properties of alpha-synuclein. J Alzheimers Dis 24(Suppl 2):211–221. doi:10.3233/JAD-2011-101965
Kurz A, Rabbani N, Walter M, Bonin M, Thornalley P, Auburger G, Gispert S (2011) Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress. Cell Mol Life Sci 68(4):721–733. doi:10.1007/s00018-010-0483-7
Negre-Salvayre A, Salvayre R, Auge N, Pamplona R, Portero-Otin M (2009) Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11(12):3071–3109. doi:10.1089/ARS.2009.2484
Coker LH, Wagenknecht LE (2011) Advanced glycation end products, diabetes, and the brain. Neurology 77(14):1326–1327. doi:10.1212/WNL.0b013e318231532b
Yamagishi S (2011) Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 46(4):217–224. doi:10.1016/j.exger.2010.11.007
Nawale RB, Mourya VK, Bhise SB (2006) Non-enzymatic glycation of proteins: a cause for complications in diabetes. Indian J Biochem Biophys 43(6):337–344
Shaikh S, Nicholson LF (2008) Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res 86(9):2071–2082. doi:10.1002/jnr.21644
Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344(Pt 1):109–116
Richard JP (1993) Mechanism for the formation of methylglyoxal from triosephosphates. Biochem Soc Trans 21(2):549–553
McPherson JD, Shilton BH, Walton DJ (1988) Role of fructose in glycation and cross-linking of proteins. Biochemistry 27(6):1901–1907
Grillo MA, Colombatto S (2008) Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 35(1):29–36. doi:10.1007/s00726-007-0606-0
Choei H, Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, Kikuchi S, Saito T (2004) Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease. Acta Neuropathol 108(3):189–193. doi:10.1007/s00401-004-0871-x
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science 293(5528):263–269. doi:10.1126/science.1060627
Cole RN, Hart GW (2001) Cytosolic O-glycosylation is abundant in nerve terminals. J Neurochem 79(5):1080–1089
Tompkins MM, Gai WP, Douglas S, Bunn SJ (2003) Alpha-synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells. Brain Res 984(1–2):233–236
Pashikanti S, Boissonneault GA, Cervantes-Laurean D (2011) Ex vivo detection of histone H1 modified with advanced glycation end products. Free Radic Biol Med 50(10):1410–1416. doi:10.1016/j.freeradbiomed.2011.01.034
Chen L, Wei Y, Wang X, He R (2010) Ribosylation rapidly induces alpha-synuclein to form highly cytotoxic molten globules of advanced glycation end products. PLoS One 5(2):e9052. doi:10.1371/journal.pone.0009052
Takeuchi M, Yamagishi S (2004) TAGE (toxic AGEs) hypothesis in various chronic diseases. Med Hypotheses 63(3):449–452. doi:10.1016/j.mehy.2004.02.042
Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1–2):91–104. doi:10.1007/s11010-010-0563-x
Munch G, Westcott B, Menini T, Gugliucci A (2010) Advanced glycation endproducts and their pathogenic roles in neurological disorders. Amino Acids. doi:10.1007/s00726-010-0777-y
Ledesma MD, Bonay P, Colaco C, Avila J (1994) Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 269(34):21614–21619
Smith MA, Perry G (1994) Alzheimer disease: an imbalance of proteolytic regulation? Med Hypotheses 42(4):277–279
Choi YG, Lim S (2010) N(Varepsilon)-(carboxymethyl)lysine linkage to alpha-synuclein and involvement of advanced glycation end products in alpha-synuclein deposits in an MPTP-intoxicated mouse model. Biochimie 92(10):1379–1386. doi:10.1016/j.biochi.2010.06.025
Munch G, Luth HJ, Wong A, Arendt T, Hirsch E, Ravid R, Riederer P (2000) Crosslinking of alpha-synuclein by advanced glycation endproducts—an early pathophysiological step in Lewy body formation? J Chem Neuroanat 20(3–4):253–257
Lee D, Park CW, Paik SR, Choi KY (2009) The modification of alpha-synuclein by dicarbonyl compounds inhibits its fibril-forming process. Biochim Biophys Acta 1794(3):421–430. doi:10.1016/j.bbapap.2008.11.016
Dalfo E, Portero-Otin M, Ayala V, Martinez A, Pamplona R, Ferrer I (2005) Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol 64(9):816–830
Acknowledgements
The authors wish to thank Mr. Arturo Melo for supporting the research through Melo Brain Grant, Republic of Panama.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guerrero, E., Vasudevaraju, P., Hegde, M.L. et al. Recent Advances in α-Synuclein Functions, Advanced Glycation, and Toxicity: Implications for Parkinson’s Disease. Mol Neurobiol 47, 525–536 (2013). https://doi.org/10.1007/s12035-012-8328-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-012-8328-z